false 0001053691 0001053691 2024-07-23 2024-07-23
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
 
July 23, 2024
Date of Report (Date of earliest event reported)
 
 
CervoMed Inc.
(Exact name of registrant as specified in its charter)
 
 
Delaware
  
001-37942
  
30-0645032
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(I.R.S. Employer
Identification No.)
   
20 Park Plaza, Suite 424
Boston, Massachusetts
  
02116
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (617) 744-4400
 
Not applicable
(Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common Stock, $0.001 par value
  
CRVO
  
NASDAQ Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 
 
 
Item 7.01
Regulation FD Disclosure
 
Virtual Key Opinion Leader Event
 
As previously announced, on July 23, 2024, CervoMed Inc. (the “Company,” “we,” or “us”) will host a virtual key opinion leader event related to neflamapimod for the treatment of patients with dementia with Lewy bodies.
 
Certain information concerning the business, clinical studies, development plans, financial position and related matters to be presented during the event has been made available on our website, www.cervomed.com, under the heading, “Investors – Events and Presentations.” Representatives of the Company may also use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with other conferences, meetings, and presentations to investors, analysts and others.
 
The information contained in the presentation is summary information that is intended to be considered in the context of the Company’s filings with the Securities and Exchange Commission (“SEC”) and other public announcements that we may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure.
 
The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K. The information in this Item 7.01 (including any information incorporated herein by reference) is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18 of the Exchange Act unless we specifically incorporate it by reference in a document filed under the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as set forth by specific reference in such a filing.
 
 
Item 9.01
Financial Statements and Exhibits
 
(d)         Exhibits
 
Exhibit No.
  
Description
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: July 23, 2024
CervoMed Inc.
By:
/s/ William Elder
Name: 
William Elder
Title:
Chief Financial Officer & General Counsel
         
 
3
v3.24.2
Document And Entity Information
Jul. 23, 2024
Document Information [Line Items]  
Entity, Registrant Name CervoMed Inc.
Document, Type 8-K
Document, Period End Date Jul. 23, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-37942
Entity, Tax Identification Number 30-0645032
Entity, Address, Address Line One 20 Park Plaza, Suite 424
Entity, Address, City or Town Boston
Entity, Address, State or Province MA
Entity, Address, Postal Zip Code 02116
City Area Code 617
Local Phone Number 744-4400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol CRVO
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001053691
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Diffusion Pharmaceuticals Charts.
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Diffusion Pharmaceuticals Charts.